Search:
  • Ranking
  • Beyond the horizon 
  • Not recommended
  • Mapping
  • CTR
  • CLA
  • Due diligence
  • Leadership team
  • Marketing materials
  • Purchase plans
  • Contact
  • log in
  • Free trial access
  • Search
    • Not recommended
    The subset “Not Recommended” contains health technologies which, in the view of MedInvest Scanner, have limited potential to replace or compete effectively with current standards of care. Each technology included in this section has been carefully evaluated on the merits of its available scientific evidence, and the reasoning behind the Not Recommended  label are provided. These reasons may include low efficacy, poor cost-effectiveness, unfavourable competitive landscape or other factors, making them less attractive as investment opportunities.
    Free trial access

    Count of all records in M.I.S. database 1,201

    Count of all records in specialities

    Count of records in Not recommended 0

    Count of records in specialities

    M.I.S. access plans
    Free trial access
    Unlimited access to 1 medical field
    Infectious diseases (Mapping + Ranking + Beyond the horizon). Click to get access
    Multiple users
    In case the nature of your work requires access to the M.I.S. Database for multiple users we can prepare a customer-specific offer. Please feel free to contact us directly to discuss more about your requirements so we could present an offer directly tailored to your needs.
    90 day access
    90 day access to M.I.S. Database
    for 1 user.
    Contact M.I.S. to find out about prices.
    Click to get access
    Short report of competitive space (SRCS) SRCS – a brief report pertaining to a competitive market segment for a particular health technology or a group of health technologies, based on the M.I.S. database, including an overview of competitive technologies entered into the M.I.S. database and their place in the Ranking as compared to the health technology which is the subject of the ordered SRCS. Detailed conditions, including the anticipated subject and scope of the report are each time determined by the Parties in a separate written agreement. SRCS costs 3,000 USD*. Click to order
    *The descriptions of services and products offered by MedInvest Scanner sp. z o.o and their prices are presented here for informational purposes only and do not constitute an offer within the meaning of the applicable provisions of law, and in particular do not constitute an offer within the meaning of Article 66 paragraph 1 of the Civil Code. MedInvest Scanner sp. z o.o reserves the right to change the scope of services and products it offers as well as their prices.